Zhongke Angel Fund

Zhongke Angel Fund

Zhongke Angel Fund launched as the venture-investment front-end for the Chinese Academy of Sciences (CAS), the sprawling state research apparatus that runs 100-plus institutes generating thousands of patent families each year. The firm's founding premise mirrors the technology-transfer model that Stanford's StartX or MIT's The Engine later pursued — gatekeeper to a closed ecosystem of labs, grant-funded prototypes, and doctorates-in-training. By 2020, Zhongke had published a portfolio of over 40 active investments, concentrated in fields where laboratory provenance creates natural barriers: quantum computing components, synthetic biology platforms, and satellite-manufacturing subsystems. The firm's deployment discipline is shaped by the cadence of CAS's Technology Transfer Centers. Zhongke leads or co-leads seed rounds between RMB 5 million and RMB 20 million, occasionally following on before Series A. Publicly verifiable portfolio names include CASI Pharmaceutical, a cell-therapy CDMO that attracted Sinopharm Capital in 2022, and Pony.ai, the autonomous-driving company it backed at the angel stage alongside Sequoia China (per the firm, 2023). The geographic footprint is overwhelmingly domestic — Shenzhen, Beijing, Hefei, and Suzhou anchor the deal map — with an emerging Hong Kong nexus for companies pursuing dual-currency IPOs. Scale is inherently difficult to track. Zhongke does not publish aggregate AUM, though its portfolio count and typical check sizes suggest an active commitment base in the hundreds of millions of RMB. The firm's website carried no record of a team page as of mid-2025, reinforcing the operational reality that deal leads are embedded in CAS institutes rather than a branded office park. September 2023: Zhongke Angel Fund participated in the RMB 200 million angel round for Tiangong Quantum, a superconducting qubit startup spun out of the Institute of Physics (per China Money Network, September 2023). No separate philanthropy or club structures are tied to the vehicle, though CAS's internal R&D budget serves a de-facto grant-pre-seed function for the pipeline. Zhongke Angel Fund's structural differentiator is its status as a fund-level extension of a national research apparatus rather than an independent general partnership. General partners evaluating competitive rounds face an information asymmetry: the firm can diligence by walking into the Beijing Institute of Nano Energy and talking to the post-doc who actually invented the material, while outside investors queue for a slide deck. That embedded position makes replication impossible and exit timing uniquely disciplined — a posture that the firm's external co-investors, including Sinopharm and Legend Capital, have evidently ratified through repeated co-deployment.